lisocabtagene maraleucel

{
  "id": "MLC-T-ONC-004872",
  "term": "lisocabtagene maraleucel",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A treatment used for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, or certain types of large B-cell lymphoma that relapsed (came back) or did not get better after treatment with at least one or two lines of systemic therapy. It is also being studied in the treatment of other types of cancer. Lisocabtagene maraleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Lisocabtagene maraleucel binds to a protein called CD19, which is found on most B-cell lymphoma cells. This helps the body’s immune system kill cancer cells. Lisocabtagene maraleucel is a type of cellular immunotherapy called CAR T-cell therapy. Also called Breyanzi.",
    "A preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T cells and antitumor activity."
  ],
  "synonyms": [
    "Breyanzi",
    "autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T lymphocytes JCAR017",
    "anti-CD19-CAR genetically engineered autologous T lymphocytes JCAR017",
    "autologous anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T lymphocytes JCAR017",
    "Liso-cel"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lisocabtagene-maraleucel/"
}